10x Genomics, Inc. TXG
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.12% | -12.65% | -2.61% | 0.61% | -1.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.12% | -12.65% | -2.61% | 0.61% | -1.75% |
| Cost of Revenue | -22.50% | -19.41% | -9.65% | -2.18% | 7.59% |
| Gross Profit | 12.58% | -10.06% | 0.70% | 1.97% | -5.72% |
| SG&A Expenses | 1.88% | 5.68% | -26.02% | -21.26% | -8.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.65% | -5.17% | -17.46% | -15.01% | -6.52% |
| Operating Income | 49.09% | -117.09% | 64.87% | 67.91% | 23.97% |
| Income Before Tax | 34.49% | -150.40% | 61.66% | 68.60% | 18.10% |
| Income Tax Expenses | 229.47% | -129.04% | -26.88% | 63.43% | -155.74% |
| Earnings from Continuing Operations | 29.29% | -151.92% | 60.80% | 66.85% | 23.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.29% | -151.92% | 60.80% | 66.85% | 23.16% |
| EBIT | 49.09% | -117.09% | 64.87% | 67.91% | 23.97% |
| EBITDA | 69.16% | -381.73% | 82.50% | 86.06% | 34.67% |
| EPS Basic | 32.16% | -149.41% | 62.53% | 68.28% | 26.07% |
| Normalized Basic EPS | 61.22% | -466.84% | 71.11% | 74.90% | 26.25% |
| EPS Diluted | 32.16% | -150.16% | 62.53% | 68.28% | 26.07% |
| Normalized Diluted EPS | 61.22% | -469.89% | 71.11% | 74.90% | 26.25% |
| Average Basic Shares Outstanding | 4.23% | 5.03% | 4.64% | 4.51% | 3.95% |
| Average Diluted Shares Outstanding | 4.23% | 4.40% | 4.64% | 4.51% | 3.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |